Many patients may keep off lost pounds after stopping a GLP-1, US data suggests
Real-world data suggests weight loss durability post-GLP-1 drug discontinuationStudy suggests weight regain may be less common than clinical…
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalledTzield pushed back after adverse event…
US FDA requests removal of suicide warnings from weight-loss drug labels
Regulator asks drugmakers to remove warnings of suicidal thoughts from GLP-1 drugs’ labelsFDA finds no link between GLP-1…
US FDA approves Vanda Pharmaceuticals’ motion sickness drug
Item 1 of 2 Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White…